RMRaffaella Melzi

Raffaella Melzi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Raffaella Melzi has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Total Pancreatectomy With Islet Autotransplantation as an Alternative to High-risk Pancreatojejunostomy After Pancreaticoduodenectomy

    by Gianpaolo Balzano, Alessandro Zerbi, Francesca Aleotti, Giovanni Capretti, Raffella Bsc Melzi, Nicolò Pecorelli, Alessia Bsc Mercalli, Rita Bsc Nano, Paola Bsc Magistretti, Francesca Gavazzi, et al.

    Objective: To compare pancreaticoduodenectomy (PD) and total pancreatectomy (TP) with islet autotransplantation (IAT) in patients at high risk of postoperative pancreatic fistula (POPF). Background: Criteria to predict the risk of POPF occurrence after PD are available. However, even when a high risk of POPF is predicted, TP is not currently accepted as an alternative to PD, because of its severe consequences on glycaemic control. Combining IAT with TP may mitigate such consequences. Methods: Randomized, open-label, controlled, bicentric trial (NCT01346098). Candidates for PD at high-risk pancreatic anastomosis (ie, soft pancreas and duct diameter ≤3 mm) were randomly assigned (1:1) to undergo either PD or TP-IAT. The primary endpoint was the incidence of complications within 90 days after surgery. Results: Between 2010 and 2019, 61 patients were assigned to PD (n=31) or TP-IAT (n=30). In the intention-to-treat analysis, morbidity rate was 90·3% after PD and 60% after TP-IAT (P=0.008). According to complications’ severity, PD was associated with an increased risk of grade ≥2 [odds ratio (OR)=7.64 (95% CI: 1.35–43.3), P=0.022], while the OR for grade ≥3 complications was 2.82 (95% CI: 0.86–9.24, P=0.086). After TP-IAT, the postoperative stay was shorter [median: 10.5 vs 16.0 days; PP<0.0001], but most patients maintained good metabolic control and showed sustained C-peptide production over time. Conclusions: TP-IAT may become the standard treatment in candidates for PD, when a high risk of POPF is predicted.


  • Open Access

    Pre-Existing Diabetes and COVID-Associated Hyperglycaemia in Patients with COVID-19 Pneumonia

    by Andrea Laurenzi, Amelia Caretto, Chiara Molinari, Elena Bazzigaluppi, Cristina Brigatti, Ilaria Marzinotto, Alessia Mercalli, Raffaella Melzi, Rita Nano, Cristina Tresoldi, et al.

    Aim. The aim of the current study was to compare clinical characteristics, laboratory findings, and major outcomes of patients hospitalized for COVID-19 pneumonia with COVID-associated hyperglycaemia or pre-existing diabetes. Methods. A cohort of 176 adult patients with a diagnosis of pre-existing diabetes (n = 112) or COVID-associated hyperglycaemia (n = 55) was studied. Results. Patients with COVID-associated hyperglycaemia had lower BMI, significantly less comorbidities, and higher levels of inflammatory markers and indicators of multi-organ injury than those with pre-existing diabetes. No differences between pre-existing diabetes and COVID-associated hyperglycaemia were evident for symptoms at admission, the humoral response against SARS-CoV-2, or autoantibodies to glutamic acid decarboxylase or interferon alpha-4. COVID-associated hyperglycaemia was independently associated with the risk of adverse clinical outcome, which was defined as ICU admission or death (HR 2.11, 95% CI 1.34–3.31; p = 0.001), even after adjustment for age, sex, and other selected variables associated with COVID-19 severity. Furthermore, at the same time, we documented a negative association (HR 0.661, 95% CI 0.43–1.02; p = 0.063) between COVID-associated hyperglycaemia to swab negativization. Conclusions. Recognizing hyperglycaemia as a specific clinical entity associated with COVID-19 pneumonia is relevant for early and appropriate patient management and close monitoring for the progression of disease severity.


  • Immunomodulation of CXCR2 Improves the Islet Engraftment and Survival after Liver Infusion

    by A. Citro, E. Cantarelli, R. Melzi, E. Dugnani, L. Daffonchio, M. Allegretti, L. Piemonti

  • Identification of Risk Factors Associated with the Induction/Increase of Donor Specific HLA Antibodies And/Or Islet Specific Autoantibodies after Islet Transplantation

    by P. Maffi, R. Nano, R. Melzi, A. Mercalli, V. Sordi, F. Poli, M. Cardillo, M. Scalamogna, V. Lampasona, M. Everly, et al.

  • Open Access

    Intrahepatic Islet Transplant in the Mouse: Functional and Morphological Characterization

    by R. Melzi, F. Sanvito, A. Mercalli, K. Andralojc, E. Bonifacio, L. Piemonti

    Although in a clinical setting islet transplantation is normally performed by percutaneous intrahepatic infusion, the kidney capsule has been the site of choice in nearly all the studies using mice. In the present study, we extensively characterized the mouse model of intraportally transplanted islets with the purpose to propose it as a model to study islet transplantation. C57BL/6 (n = 78) and BALB/C (n = 53) recipients were transplanted with 400 autologous islets alternatively through the portal vein (PV-Tx) or under the kidney capsule (KC-Tx). Glucose concentration during the first hour after syngeneic islet infusion was associated with subsequent long-term function confirming that early events have long-term effects on graft function. In both strains tested the probability to achieve islet function was significantly lower for PV-Tx than KC-Tx. Also in allogeneic models (C57BL/6 to BALB/C, n = 104; BALB/C to C57BL/6, n = 77) the probability to achieve primary function was significantly lower for PV-Tx than KC-Tx and the site of transplantation significantly affected the graft survival. Histological evaluation of livers showed the presence of features (embolism, thrombosis, focal areas of liver necrosis) that are absent in the kidney subcapsular site. Finally, significant differences in the outcome of PV-Tx were observed between the Th type 1 inflammatory-prone C57BL/6 mouse and the type 2 inflammatory-prone BALB/C mouse. Intraportal islet graft model has some features that are more similar to human clinical islet transplantation and should be used as a model to study not only engraftment but also mechanisms of immune suppression and immune tolerance.